Who is sponsoring NCT01087671?

NCT01087671 is sponsored by Santen Oy.

What condition does NCT01087671 study?

NCT01087671 studies Ocular Hypertension, Open-Angle Glaucoma.

What is the status of NCT01087671?

NCT01087671 is currently COMPLETED.

Last reviewed 2013-05-30 · How we verify

Ocular Signs and Symptoms in Patients With Ocular Hypertension or Open-angle Glaucoma Switched From Preserved Latanoprost 0.005% Eye Drops to Preservative Free Tafluprost Eye Drops

NCT01087671 Phase 3 COMPLETED

The purpose of this study is to investigate if changes in ocular signs and symptoms occur in patients with ocular hypertension or glaucoma when they switch from latanoprost 0.005% (Xalatan) to preservative free Tafluprost eye drops.

Details

Lead sponsor	Santen Oy
Phase	Phase 3
Status	COMPLETED
Enrolment	185
Start date	2010-04
Completion	2010-10

Conditions

Ocular Hypertension
Open-Angle Glaucoma

Interventions

tafluprost

Primary outcomes

Assessment of changes in ocular symptoms and signs — From Screening (Visit 1) to12 weeks.
Ocular symptoms include: irritation/burning/stinging, foreign body sensation, tearing, itching and dry eye sensation. Following signs will be evaluated: tear break-up time, corneal and conjunctival fluorescein staining, blepharitis, conjunctival redness and tear secretion (schirmer test).